Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Stock Market Shifts into Small Caps

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Aug 05, 2024 9:49pm

110 Views

Post# 36165282

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Stock Market Shifts into Small Caps

August 05, 2024 - Why Fund Managers Fell Behind The Small Cap Rally

Fund managers were caught off guard. “Funds were heavily underweight Small Size and High Dividend Yield, two of the top performing factors last month, and overweight Momentum, one of the biggest laggards,” wrote BofA Securities analysts in a note Monday.

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing